Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current
-
ナレーター：
-
著者：
In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.
In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.
Learn More Here